Logo image of ANVS

ANNOVIS BIO (ANVS) Stock Fundamental Analysis

NYSE:ANVS - New York Stock Exchange, Inc. - US03615A1088 - Common Stock - Currency: USD

1.69  +0.03 (+1.81%)

Premarket: 1.73 +0.04 (+2.37%)

Fundamental Rating

2

Overall ANVS gets a fundamental rating of 2 out of 10. We evaluated ANVS against 571 industry peers in the Biotechnology industry. The financial health of ANVS is average, but there are quite some concerns on its profitability. ANVS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ANVS has reported negative net income.
ANVS had a negative operating cash flow in the past year.
ANVS had negative earnings in each of the past 5 years.
ANVS had a negative operating cash flow in each of the past 5 years.
ANVS Yearly Net Income VS EBIT VS OCF VS FCFANVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M -50M

1.2 Ratios

ANVS has a Return On Assets of -285.06%. This is amonst the worse of the industry: ANVS underperforms 92.47% of its industry peers.
ANVS's Return On Equity of -579.57% is on the low side compared to the rest of the industry. ANVS is outperformed by 79.68% of its industry peers.
Industry RankSector Rank
ROA -285.06%
ROE -579.57%
ROIC N/A
ROA(3y)-217.47%
ROA(5y)-161.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANVS Yearly ROA, ROE, ROICANVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 500 -500 -1K

1.3 Margins

ANVS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANVS Yearly Profit, Operating, Gross MarginsANVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for ANVS has been increased compared to 1 year ago.
ANVS has more shares outstanding than it did 5 years ago.
ANVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ANVS Yearly Shares OutstandingANVS Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
ANVS Yearly Total Debt VS Total AssetsANVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

2.2 Solvency

Based on the Altman-Z score of -16.10, we must say that ANVS is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -16.10, ANVS is doing worse than 81.96% of the companies in the same industry.
There is no outstanding debt for ANVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -16.1
ROIC/WACCN/A
WACCN/A
ANVS Yearly LT Debt VS Equity VS FCFANVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 2.66 indicates that ANVS has no problem at all paying its short term obligations.
ANVS has a worse Current ratio (2.66) than 69.00% of its industry peers.
A Quick Ratio of 2.66 indicates that ANVS has no problem at all paying its short term obligations.
With a Quick ratio value of 2.66, ANVS is not doing good in the industry: 67.08% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.66
Quick Ratio 2.66
ANVS Yearly Current Assets VS Current LiabilitesANVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 14.99% over the past year.
EPS 1Y (TTM)14.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.49%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ANVS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.08% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y69.55%
EPS Next 2Y29.4%
EPS Next 3Y18.89%
EPS Next 5Y15.08%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANVS Yearly Revenue VS EstimatesANVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ANVS Yearly EPS VS EstimatesANVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ANVS. In the last year negative earnings were reported.
Also next year ANVS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANVS Price Earnings VS Forward Price EarningsANVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANVS Per share dataANVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as ANVS's earnings are expected to grow with 18.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.4%
EPS Next 3Y18.89%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ANVS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANNOVIS BIO

NYSE:ANVS (3/5/2025, 8:04:00 PM)

Premarket: 1.73 +0.04 (+2.37%)

1.69

+0.03 (+1.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-08 2024-11-08/amc
Earnings (Next)03-27 2025-03-27/amc
Inst Owners13.3%
Inst Owner Change36.71%
Ins Owners14.4%
Ins Owner Change0%
Market Cap32.94M
Analysts81.67
Price Target39.02 (2208.88%)
Short Float %8.66%
Short Ratio2.56
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-15.32%
Min EPS beat(2)-80.79%
Max EPS beat(2)50.15%
EPS beat(4)2
Avg EPS beat(4)-2.82%
Min EPS beat(4)-80.79%
Max EPS beat(4)87.72%
EPS beat(8)4
Avg EPS beat(8)-29.3%
EPS beat(12)5
Avg EPS beat(12)-41.9%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.91%
PT rev (3m)9.91%
EPS NQ rev (1m)-8.57%
EPS NQ rev (3m)6.21%
EPS NY rev (1m)-0.27%
EPS NY rev (3m)-1.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.66
P/tB 4.66
EV/EBITDA N/A
EPS(TTM)-3.63
EYN/A
EPS(NY)-2
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0
BVpS0.36
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -285.06%
ROE -579.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-217.47%
ROA(5y)-161.61%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.66
Quick Ratio 2.66
Altman-Z -16.1
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)14.99%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.49%
EPS Next Y69.55%
EPS Next 2Y29.4%
EPS Next 3Y18.89%
EPS Next 5Y15.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y19.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year46.72%
EBIT Next 3Y-11.05%
EBIT Next 5Y-29.35%
FCF growth 1Y-48.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.52%
OCF growth 3YN/A
OCF growth 5YN/A